CSIMarket
 
Transmedics Group Inc   (NASDAQ: TMDX)
Other Ticker:  
 
 
Price: $113.3200 $-2.36 -2.040%
Day's High: $118.37 Week Perf: -9.18 %
Day's Low: $ 113.04 30 Day Perf: -20.78 %
Volume (M): 716 52 Wk High: $ 177.32
Volume (M$): $ 81,103 52 Wk Avg: $106.13
Open: $117.37 52 Wk Low: $55.00



 Market Capitalization (Millions $) 4,523
 Shares Outstanding (Millions) 40
 Employees 194
 Revenues (TTM) (Millions $) 488
 Net Income (TTM) (Millions $) 49
 Cash Flow (TTM) (Millions $) -40
 Capital Exp. (TTM) (Millions $) 113

Transmedics Group Inc
TransMedics Group Inc. (NASDAQ: TMDX) is a medical technology company headquartered in Andover, Massachusetts that is dedicated to improving organ transplant outcomes. The company was founded in 1998 and has since developed innovative solutions to maintain organ viability during transportation, known as the Organ Care System (OCS).

The OCS is a portable platform that enables organ transplants by providing uninterrupted blood flow, oxygenation, and preservation of organs during transportation. The OCS is compatible with a variety of organ types, including hearts, lungs, and livers, and has been shown to increase the number of organs suitable for transplantation and improve transplant outcomes.

TransMedics is focused on increasing patient access to transplants by improving organ preservation and reducing the risk of transplant-related complications. The company is dedicated to delivering innovative tools and services that can significantly increase the number of organs available for transplantation.

The company has a global presence, with a presence in Europe, the United States, and Asia. TransMedics has commercialized the OCS in over 30 countries and has obtained regulatory approval for its products from major regulatory authorities, including the United States, Europe, Canada, and Australia.

TransMedics has also received numerous awards and accolades for its innovative technology, including being named a finalist in the 2021 Edison Best New Product Awards for its OCS LUNG platform.

TransMedics is positioned for continued growth, with a strong pipeline of ongoing clinical trials and a dedicated team of experts working to develop new solutions that are transforming the field of organ transplant medicine. The company is committed to bringing its innovative technologies to organ transplant patients around the world, providing hope and new opportunities for those in need of life-saving transplants.


   Company Address: 200 Minuteman Road Andover 1810 MA
   Company Phone Number: 552-0900   Stock Exchange / Ticker: NASDAQ TMDX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRC   -1.11%    
BAX   -1.11%    
EW   -2.45%    
IART   -3.89%    
LIVN   -3.02%    
PEN   -1.48%    
• View Complete Report
   



Announcement

Investors Urged to Act Rosen Law Firm Encourages TransMedics Group Shareholders to Participate in Class Action Ahead ...

Published Tue, Mar 25 2025 4:39 PM UTC

In a crucial development for investors of TransMedics Group, Inc. (NASDAQ: TMDX), the Rosen Law Firm, a leading advocate for investor rights, has issued a reminder to shareholders who purchased securities in the company between February 28, 2023, and January 10, 2025. The firm highlights the importance of the upcoming deadline for lead plaintiffs, set for April 15, 2025, in ...

Announcement

TransMedics Group Faces Investor Lawsuit, Raising Concerns Over Corporate Governance and Market Confidence

Published Mon, Mar 3 2025 7:39 PM UTC

In a noteworthy development for TransMedics Group, Inc. (NASDAQ: TMDX), investors have been alerted to a pending class action lawsuit, with a lead plaintiff deadline set for April 15, 2025. The Gross Law Firm, representing the interests of affected shareholders, has issued a formal announcement to notify stakeholders about the lawsuit, signaling potential legal turbulence on...

Announcement

Investigative Developments Surrounding TransMedics Group, Inc. Shareholders Encouraged to Pursue Legal Rights Followi...

Published Fri, Feb 7 2025 8:20 PM UTC

In a significant development within the financial landscape, TransMedics Group, Inc. (NASDAQ: TMDX) finds itself under scrutiny amid allegations suggesting that the company has disseminated materially misleading business information to the investing public. The Rosen Law Firm, renowned for its global investor rights advocacy, is actively investigating potential securities cl...

Announcement

TransMedics Soars Amid Inquiry Investors Encouraged to Assess Potential Claims

Published Sun, Feb 2 2025 6:09 PM UTC

In a timely revelation, TransMedics Group, Inc. (NASDAQ: TMDX) finds itself under the microscope of both the investing community and regulatory scrutiny. The Rosen Law Firm, a prominent global investor rights law firm, has announced an investigation into potential securities claims on behalf of shareholders. The focus of this inquiry centers on allegations that TransMedics m...

Announcement

Legal Scrutiny Grows Regarding Allegations of Misleading Statements by TransMedics Group, Inc.

Published Sat, Jan 25 2025 9:17 PM UTC

Report: TransMedics Group, Inc. a company listed on the NASDAQ under the ticker symbol TMDX, is currently under investigation by The Rosen Law Firm, a prominent global investor rights law firm. The investigation pertains to potential securities claims on behalf of shareholders who may have experienced financial losses as a result of the company?s alleged dissemination of ma...







Transmedics Group Inc's Segments
OCS transplant revenue    99.4 % of total Revenue
United States OCS transplant revenue    96.57 % of total Revenue
All Other Countries OCS transplant revenue    2.83 % of total Revenue
Lung revenue United States OCS transplant revenue    2.53 % of total Revenue
Lung revenue All Other Countries OCS transplant revenue    0.26 % of total Revenue
Heart revenue United States OCS transplant revenue    18.3 % of total Revenue
Heart revenue All Other Countries OCS transplant revenue    2.47 % of total Revenue
Liver revenue United States OCS transplant revenue    75.74 % of total Revenue
Liver revenue All Other Countries OCS transplant revenue    0.1 % of total Revenue
Unrelated to OCS Transplant    0.63 % of total Revenue
Cost of Net Product Revenue    61.47 % of total Revenue
Cost of Service Revenue    38.53 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com